These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12621161)

  • 1. Preventing angiographic progression of coronary atherosclerosis with pravastatin.
    Daida H; Ouchi Y; Saito Y; Yamada N; Nishide T; Mokuno H; Kurata T; Sato H; Eto M; Ako JY; Tango T; Yamaguchi H;
    J Atheroscler Thromb; 2003; 10(1):25-31. PubMed ID: 12621161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
    Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
    Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
    Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
    Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
    Kawaguchi A; Mitsudo K; Nobuyoshi M; Minamino R; Hayasaki K; Nakashima M; Yamamoto A;
    J Cardiovasc Risk; 2002 Feb; 9(1):7-16. PubMed ID: 11984212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
    Tamura A; Mikuriya Y; Nasu M
    Am J Cardiol; 1997 Apr; 79(7):893-6. PubMed ID: 9104901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
    Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
    Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
    Sakamoto K; Sakamoto T; Ogawa H;
    Clin Ther; 2006 Jul; 28(7):1012-21. PubMed ID: 16990079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
    de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
    Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
    Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
    J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial.
    Schwartz RG; Pearson TA; Kalaria VG; Mackin ML; Williford DJ; Awasthi A; Shah A; Rains A; Guido JJ
    J Am Coll Cardiol; 2003 Aug; 42(4):600-10. PubMed ID: 12932588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
    de Groot E; Jukema JW; Montauban van Swijndregt AD; Zwinderman AH; Ackerstaff RG; van der Steen AF; Bom N; Lie KI; Bruschke AV
    J Am Coll Cardiol; 1998 Jun; 31(7):1561-7. PubMed ID: 9626835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
    Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
    Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
    Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
    J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
    Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
    Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.